Probucol 4,4′-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol) is a synthetic molecule clinically used for prevention and treatment of hypercholesterolemia and atherosclerosis. Recent studies have shown that the beneficial effects of probucol mainly derive from its anti-inflammatory and antioxidant properties. Gramnegative bacteria are common infectious agents and their wall components, e.g. lipopolysaccharide (LPS), are important elicitors of inflammation. LPS is sensed by tissue resident cells and it triggers a Toll-like receptor 4/ MyD88-dependent signaling cascade resulting in endothelial activation, leukocyte recruitment and nociception. Therefore the present study aimed to investigate the anti-inflammatory and analgesic effects of probucol in models of LPS-induced acute inflammation. Probucol at 0.3-30 mg/kg was administrated to male Swiss mice per oral 1 h before intraplantar or intraperitoneal lipopolysaccharide stimulus. Probucol at 3 mg/kg reduced lipopolysaccharide-induced mechanical and thermal hyperalgesia. These effects were accompanied by reduced leukocyte influx and cytokine production in both paw skin and peritoneum exudate. Unexpectedly, probucol did not alter lipopolysaccharide-induced tissue oxidative stress at anti-inflammatory /analgesic dose. On the other hand, probucol inhibited lipopolysaccharide-induced nuclear factor kappa B (NF-кB) activation in paw tissue as well as NF-кB activity in cultured macrophages in vitro, reinforcing the inhibitory effect of probucol over the NF-кB signaling pathway. In this sense, we propose that probucol acts on resident immune cells, such as macrophages, targeting the NF-кB pathway. As a result, it prevents the amplification and persistence of the inflammatory response by attenuating NF-кB-dependent cytokine production and leukocyte recruitment explaining its analgesic effects as well.
Introduction
Lipopolysaccharide (LPS) is one of the main constituents of Gramnegative bacteria cell wall and the prototypical agonist of Toll-like receptor 4, a pattern recognition receptor expressed by many cell types including macrophages, monocytes and granulocytes (Nikaido, 2003; Vaure and Liu, 2014) . Binding of LPS to Toll-like receptor 4 activates a downstream signaling cascade leading to activation and nuclear translocation of nuclear factor kappa B (NF-кB) followed by production of pro-inflammatory cytokines such as Interleukin (IL)-1β, IL-6, Tumor necrosis factor-alpha (TNF-α), Interferon-gamma (IFN-γ) (Cho et al., 2016; Pinho-Ribeiro et al., 2016; Ruiz-Miyazawa et al., 2015b; Yuan et al., 2011) . These mediators largely contribute to the amplification of the inflammatory response and its clinical manifestations. For instance, IL-1β and TNF-α activate endothelial cells favoring leukocyte recruitment in addition to modulation of immune cells and sensory neurons (Binshtok et al., 2008; Jin and Gereau, 2006; Oliveira et al., 2008; Wyble et al., 1997) . Furthermore IFN-γ and IL-6 play important roles in macrophage modulation. Both cytokines induce differentiation of monocytes into macrophages (Chomarat et al., 2000; Munder et al., 1998) . IL-6 is secreted by endothelial cells and promotes the switch from neutrophil to monocyte migration by increasing monocyteattracting chemokines and reducing neutrophil-attracting ones (Hurst et al., 2001; Kaplanski et al., 2003) . In addition to its pro-inflammatory properties an increasing number of studies have shown the participation of IL-6 in pain signaling (Cunha et al., 1992; Murphy et al., 1999; Yang et al., 2015) .
Infectious diseases are a major public health concern and gramnegative bacteria arise as important causative agents of nosocomial infections (Ho et al., 2010) . The host immune response and the use of antibiotics culminate in the release of large amounts of LPS (Ginsburg and Koren, 2008) . In turn LPS contributes to disease morbidity by triggering pain signaling in a Toll-like receptor 4-dependent manner (Calil et al., 2014) . In that sense, targeting Toll-like receptor 4 downstream signaling such as the NF-кB pathway is of great importance in preventing deleterious effects of Gram-negative bacterial infections. Therefore molecules presenting anti-inflammatory and analgesic properties emerge as candidates for treating LPS-induced inflammation and hyperalgesia.
Probucol 4,4′-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol) is a synthetic compound clinically used for the treatment of hypercholesterolemia. Its anti-inflammatory and antioxidant effects were shown in experimental models of diabetes, neurodegenerative diseases and brain ischemia (Al-Majed, 2011; Colle et al., 2013; Fu et al., 2015; Li et al., 2011) . For instance probucol inhibits production of proinflammatory cytokines IL-1β, TNF-α and IL-6 in vivo and in vitro Ku et al., 1990 Ku et al., , 1988 Li et al., 2011; Liu et al., 2000; Zhang et al., 2009) . Additionally probucol was shown to attenuate NF-кB activation in endothelial cells (Aoki et al., 2001; Chen et al., 2003; Zhang et al., 2013) . Overall these findings support the beneficial effects of probucol in experimental models of inflammation-driven diseases. Given that the inflammatory response evoked by gram-negative bacteria strongly contribute to disease morbidity, this study aimed to evaluate the effects of probucol in LPS-induced acute inflammatory pain and leukocyte recruitment.
Materials and methods

Animals
Male Swiss (20-25 g) from Universidade Estadual de Londrina, Parana, Brazil and Lysm-eGFP mice (20-25 g) kindly provided by Ribeirão Preto Medical School were used in this study. Mice were housed in standard clear plastic cages, and received food and water ad libitum under a 12:12 h light/dark cycle at 21°C. All behavior testing were performed between 9 am and 5 pm in temperature-controlled room. The Animal Welfare and Ethics Committee of Londrina State University approved this study (process number 1012.2015.74) . All efforts were made to minimize the number of animals used and their suffering.
Drugs
Materials were obtained from the following sources: LPS from Escherichia coli 0111:B4 (Santa Cruz Biotechnology, Dallas, TX, USA), Naringenin (Santa Cruz Biotechnology, Dallas, TX, USA), Probucol (Santa Cruz Biotechnology, Dallas, TX, USA), Rhodamine 6G (Santa Cruz Biotechnology, Dallas, TX, USA).
Experimental procedures
Mice were treated with probucol (0.3, 3, 30 mg/kg, per oral) or vehicle (Tween 80 5% in saline) 1 h before the administration of LPS. Leukocyte recruitment into the peritoneal cavity was assessed 6 h after i.p. administration of LPS (200 ng/200 μl/cavity). Mechanical hyperalgesia and thermal hyperalgesia were evaluated 1, 3 and 5 h after i.pl. administration of LPS (200 ng/20 μl). Paw skin was collected for assessment of leukocyte recruitment by myeloperoxidase and Nacetylglucosaminidase activity assays 5 h after LPS injection. 2,2′-Azinobis-3-ethylbenzothiazoline 6-sulfonic acid (ABTS), reduced glutathione (GSH), Nitroblue tetrazolium (NBT) and Thiobarbituric Acid Reactive Substances assays (TBARS) were performed using paw skin collected 3 h after LPS injection. IL-1β, TNF-α, IL-6 and IFN-γ levels were also evaluated 3 h after LPS injection in the paw or 6 h post-LPS injection in the peritoneum exudate by enzyme-linked immunosorbent assay (ELISA). Phosphorylated and total NF-кB ratio (activation) was evaluated 3 h after LPS injection in the paw by ELISA kits. Doses of stimulus and time points of sample collection were based on previous studies in our laboratory (Pinho-Ribeiro et al., 2016; Ruiz-Miyazawa et al., 2015a) . Confocal microscopy was performed to evaluate neutrophil recruitment 4 h after LPS intraperitoneal stimulus (Marques et al., 2015) . RAW 264.7 macrophages kindly provided by Ribeirão Preto Medical School were treated with probucol (0.05-5 μM) 1 h prior to exposure to LPS (1 μg/ml). Six h after LPS stimulus, supernatants and cell lysates were obtained to evaluate IL-1β, TNF-α, IL-6 and IFN-γ levels by ELISA, and NF-кB activity was also evaluated in RAW 264.7 macrophages by the luciferase gene reporter assay.
Mechanical hyperalgesia test
Mechanical hyperalgesia was assessed by an electronic version of von Frey filaments (Cunha et al., 2004) . A handheld force transducer (electronic anesthesiometer; Insight, Ribeirao Preto, SP, Brazil) adapted with a 0.5 mm 2 polypropylene tip was used to evoke hind paw nociceptive withdrawal response. The intensity of the pressure (in g) at the moment of paw withdrawal was automatically recorded. The mechanical threshold was tested before (baseline) and after LPS i.pl. administration (200 ng/paw). The results are expressed as delta (Δ) withdrawal threshold (in g), obtained by subtracting the measurements at each time point (1, 3 and 5 h after i.pl. LPS injection) from the baseline values.
Thermal hyperalgesia test
Animals were place on a hot plate apparatus (Insight, Ribeirao Preto, SP, Brazil) at a constant temperature of 52°C. The end-point was characterized by removal of the paw followed by flinching or licking the paw, and latency time until the end-point reaction was determined (Kuraishi et al., 1983) . Maximum latency until end-point was set at 25 s to avoid tissue damage. The results are expressed as means of latency (s) within experimental groups.
Myeloperoxidase and N-acetylglucosaminidase activity assays
Myeloperoxidase and N-acetylglucosaminidase kinetic-colorimetric assays were performed as indirect indicators of neutrophil and macrophage recruitment to paw tissue, respectively. Paw skin samples were collected 5 h after LPS injection and homogenized in ice-cold K 2 HPO 4 buffer (400 μl, 50 mM, pH 6.0) containing hexadecyltrimethylammonium bromide (HTAB) (0.5% weight/volume) using a tissue-tearor (Biospec, Bartlesville, OK, USA). Samples were centrifuged (16,100g × 2 min × 4°C) and the supernatants were used for both assays. The myeloperoxidase activity assay was performed as previously described (Bradley and Christensen, 2016) . Briefly, 50 mM phosphate buffer, pH 6.0 containing 0.167 mg/ml o-dianisidine dihydrochloride and 0.015% hydrogen were added to samples and the absorbance was read at 450 nm (Multiskan GO Microplate Spectrophotometer, Thermo Scientific, Vantaa, Finland) . The values obtained were compared to a standard curve of neutrophils and results are expressed as myeloperoxidase activity (neutrophils x 10 6 / g of tissue). The N-acetylglucosaminidase activity assay was performed as previously described (Barcelos et al., 2005) . Samples were diluted in citrate/phosphate buffer (0.1 M citric acid, 0.1 M Na 2 HPO 4 , pH 4.5) in a proportion of 5:1. p-nitrophenyl-N-acetyl-β-glucosaminide dissolved in citrate/phosphate buffer was added to samples followed by addition of 0.2 M glycine buffer (pH 10.6). The absorbance was read at 405 nm (Multiskan GO, Thermo Scientific). The values obtained were compared to a standard curve of macrophages and results are expressed as N-acetylglucosaminidase activity (macrophages × 10 6 / g of tissue).
Leukocyte recruitment into the peritoneal cavity
Leukocyte recruitment into the peritoneal cavity was assessed 6 h after i.p. administration of LPS (200 ng/cavity). The dose of the inflammatory stimulus was based on previous studies performed in our laboratory (Pinho-Ribeiro et al., 2016; Ruiz-Miyazawa et al., 2015a) . Peritoneal cavities were washed with 1 ml of phosphatebuffered saline. Total leukocyte counts were performed after dilution of peritoneal exudate in Turk solution (2% acetic acid) using a Neubauer chamber. Differential cell counts were performed using the Fast Panoptic Kit for histological analysis (Laborclin, Pinhas, BR, Brazil) to distinguish polymorphonuclear from mononuclear cells under a light microscope (Olympicus Optical Co., Hamburg, Germany). The results are expressed as number of cells × 10 6 per cavity.
Total antioxidant capacity
Antioxidant capacity was assessed by the ABTS assay. This test was adapted to a 96-well microplate format as previously described (Navarro et al., 2013) . Paw skin samples were collected 3 h after i.pl. stimulus (LPS 200 ng/paw) and homogenized with a tissue-tearor in ice-cold KCl buffer (500 μl, 1.15% w/v). Samples were centrifuged at 835g at 4°C for 10 min, and supernatants were used. ABTS assay was performed as an indicator of the sample's ability to scavenge the free radical ABTS. Diluted ABTS solution was added to samples and the absorbance was measured at 730 nm after 6 min of incubation at 25°C (Multiskan GO, Thermo Scientific). The results were equated against a standard Trolox curve (0.02-20 nmol) and expressed as nmol Trolox eq. per mg of tissue.
GSH levels measurement
Paw skin samples were collected 3 h after i.pl. stimulus (LPS 200 ng/paw) and stored at −80°C for at least 48 h. For the assay, samples were homogenized with a tissue-tearor in 200 μl of 0.02 M ethylene-diamine-tetra-acetic acid (EDTA) after thawing. Trichloroacetic acid 50% solution was added to homogenates and the mixture was homogenized for 15 min using a vortex followed by centrifugation (1500g × 15 min × 4°C). The supernatants were added to a 96-well microplate followed by addition of 0.2 M TRIS buffer, pH 8.2, and 0.01 M 5,5-dithio-bis-2-nitrobenzoic acid (DTNB). The absorbance was measured at 412 nm (Multiskan GO, Thermo Scientific) after 5 min incubation at room temperature. The values obtained were compared to a standard curve of GSH. The results are expressed as GSH levels (nmol) per mg of tissue (Navarro et al., 2013) .
Superoxide anion production
Superoxide anion production was assessed by the NBT assay. Paw skin samples were collected 3 h after i.pl. stimulus (LPS 200 ng/paw). Samples were homogenized with a tissue-tearor in 500 μl of ice-cold KCl buffer (1.15% w/v) and the homogenates were used for the assay. The test was adapted to a microplate as previously described . The NBT reduction was measured at 600 nm (Multiskan GO, Thermo Scientific). The results are expressed as optical density (OD) per mg of tissue.
Lipid peroxidation
Lipid peroxidation was measured by the TBARS assay. Paw skin samples were collected 3 h after i.pl. stimulus (LPS 200 ng/paw) and homogenized with a tissue-tearor in ice-cold KCl buffer (500 μl, 1.15% w/v). The test was adapted to a microplate as previously described . The intermediate product of lipid peroxidation malondialdehyde (MDA) was determined by subtracting the absorbance at 535 nm from the absorbance at 572 nm Multiskan GO, Thermo Scientific. The results are expressed as nmol of MDA per mg of tissue.
Cytokine measurement
Paw skin samples were collected 3 h after stimulus (LPS 200 ng/ paw). Samples were homogenized with a tissue-tearor in 500 μl of icecold buffer with protease inhibitors followed by centrifugation (835g × 15 min × 4°C). Peritoneal exudates were collected using a micropipette after washing the peritoneal cavity with 1 ml of phosphate-buffered saline 6 h after stimulus (LPS 200 ng/cavity.) The supernatants of paw skin homogenates and peritoneal exudates were used to determine IL-1β, TNF-α, IL-6 and IFN-γ levels by ELISA using commercial kits (eBioscience, San Diego, CA, USA). Absorbance was measured at 450 nm (Multiskan GO, Thermo Scientific). The results are expressed as picograms of cytokines per 100 mg of tissue or ml.
NF-кB activation
Paw skin samples were collected 3 h after stimulus (LPS 200 ng/ paw). Samples were homogenized with a tissue-tearor in 400 μl of icecold lysis buffer (Cell Signaling, Danvers, MA, USA) followed by centrifugation (16.100g × 10 min × 4°C). The supernatants were used for determination of phosphorylated NF-кB p65 subunit and total NF-кB p65 subunit levels using ELISA PathScan Kits (Cell Signaling, Danvers, MA, USA) according to the manufacturer's directions. Absorbance was measured at 450 nm (Multiskan GO, Thermo Scientific). The results are expressed as IOD ratio (p-NF-кB p65/total NF-кB p65).
Immunofluorescence
Lysm e-GFP mice were euthanized with isoflurane 4 h after LPS stimulus (200 ng/cavity). A midline laparotomy was performed to remove the mesentery, which was placed on a stage as previously described (Marques et al., 2015) . Rhodamine 6G was administrated intravenously 5 min before euthanasia for background staining. Imaging was performed using a confocal microscope (Leica TCS SP8, Leica, Wetzlar, Germany) with a 40x long distance objective. Images were processed using Leica EL6000 software (Leica, Wetzlar, Germany). The results are expressed as number of neutrophils per mm³ of tissue.
Cell culture
RAW 264.7 murine macrophages were routinely cultured in RPMI medium supplemented with 10% fetal bovine serum and penicillinstreptomycin at 37°C, 5% CO 2 . To evaluate the effect of probucol in vitro, RAW 264.7 macrophages culture in 24-well plates for 24 h prior to experiments (3×10 5 cells per well). Cells were then treated with probucol (0.05-5 μM) for 1 h before stimulation with LPS (1 μg/ml). Pro-inflammatory cytokines IL-1β, TNF-α and IL-6 were measured by ELISA in the supernatants collected 6 h after stimulus. The results are expressed as pg per ml. After determining the ideal concentration of probucol (5 μM), RAW 264.7 murine macrophages stably expressing the Renilla luciferase reporter gene under the transcriptional control of an NF-кB response element (Imgenex, USA) were cultured as described above. The intracellular contents were obtained by washing the adherent cells with lysis buffer. The luciferase activity in cell lysates was determined on a luminometer (Victor X5, PerkinElmer, Waltham, MA) using the Dual Luciferase Reporter assay system (Promega, WA, USA). The results are expressed as fold-change. The NF-kB activity was normalized with respect to the basal activity of non-stimulated cells (Kumar et al., 2015) . Lactate dehydrogenase (LDH) activity was measured in supernatants to evaluate cytotoxicity using the LDH Cytotoxicity Assay Kit (Labtest, MG, Brazil). The assay and data analysis were performed according to the manufacturer's directions. The results are expressed as LDH activity (U/ml).
Statistical analyses
Results are presented as mean ± S.E.M. of measurements made on 6 mice per group per experiment, and are representative of two independent experiments. Two-way repeated measures analysis of variance (ANOVA) followed by Tukey's post hoc were used to compare groups and doses at all time points when responses were measured at different time points after stimulus injection (mechanical and thermal hyperalgesia tests). One-way ANOVA followed by Tukey's post-hoc was performed for data from single time point experiments. P < 0.05 was considered statistically significant. All data analyses were performed using GraphPad Prism® 5.0 (GraphPad Software, Inc., USA-500.288), as well as elaboration of figures. Schematic representations were elaborated using Servier and Somersault 18:24 free databases of scientific illustrations.
Results
Probucol inhibits LPS-induced leukocyte recruitment into the peritoneal cavity
Mice were treated with probucol (0.3, 3 or 30 mg/kg, p.o.) or vehicle (Tween 80 5% in saline) 1 h before i.p. administration of LPS (200 ng/cavity). Peritoneal exudates were harvested 6 h after LPS stimulus to evaluate leukocyte recruitment into the peritoneal cavity. Probucol at 0.3 mg/kg did not inhibit total, polymorphonuclear or mononuclear leukocyte recruitment (Fig. 1) . In turn probucol at 3 and 30 mg/kg reduced total leukocyte recruitment induced by LPS (61% and 69%, respectively) as well as polymorphonuclear (62% and 69%, respectively) and mononuclear (57% and 73%, respectively) cell migration to the peritoneal cavity (Fig. 1) . Since no statistical differences were observed between these two doses, probucol at 3 mg/kg was chosen for the following in vivo experiments. To further confirm the effect of probucol on neutrophil recruitment, Lysm-eGFP mice were treated with probucol at 3 mg/kg, p.o. or vehicle (Tween 80 5% in saline) 1 h before i.p. administration of LPS (200 ng/cavity). The mesentery was removed 4 h later and imaging analysis was performed to evaluate neutrophil recruitment. Probucol at 3 mg/kg inhibited 75% of LPS-induced neutrophil recruitment (Fig. 2). 3.2. Probucol inhibits LPS-induced mechanical and thermal hyperalgesia as well as neutrophil and macrophage recruitment in the paw skin Mice were treated with probucol at 3 mg/kg, p.o. or vehicle (Tween 80 5% in saline) 1 h before i.pl. administration of LPS (200 ng/paw). Mechanical and thermal hyperalgesia were evaluated at 1, 3 and 5 h after LPS injection. LPS induced mechanical and thermal hyperalgesia at all times points (P < 0.05). Probucol at 3 mg/kg reduced mechanical hyperalgesia 3 and 5 h after LPS (up to 44%) (Fig. 3A) . In turn, probucol inhibited LPS-induced thermal hyperalgesia at all time points, up to 91%. Thermal threshold was not statistically different from saline group at 3 h and 5 h (P > 0.05) (Fig. 3B) . In addition, probucol at 3 mg/kg has reduced cell recruitment in the paw. Paw tissue was removed 5 h after LPS stimulus (200 ng/paw) and the samples were used to evaluate myeloperoxidase and N-acetylglucosaminidase activities as markers of neutrophil and macrophage recruitment, respectively. Probucol reduced 59% of LPS-induced myeloperoxidase activity (Fig. 3C) and 65% of N-acetylglucosaminidase activity (Fig. 3D) . Considering that the group treated with probucol alone did not alter basal responses in Figs. 1-3, this group was not performed in the following experiments.
Probucol does not inhibit LPS-induced reactive oxygen species production in the paw skin
Mice were treated with probucol at 3 mg/kg, p.o. or vehicle (Tween 80 5% in saline) 1 h before i.pl. administration of LPS (200 ng/paw). Another group received the antioxidant naringenin at 50 mg/kg 1 h before LPS stimulus (Pinho-Ribeiro et al., 2016) . Paw skin samples were collected 3 h after LPS injection to evaluate the following parameters of oxidative stress: ABTS free radical scavenging ability, GSH levels, lipid peroxidation by TBARS and superoxide anion formation by NBT reduction. LPS induced tissue oxidative stress observed as reduction of ABTS scavenging ability (35%) and GSH levels (64%) as well as increase of lipid peroxidation (TBARS assay, 58%) and superoxide anion formation (NBT reduction, 330%) compared to the saline group. Naringenin at 50 mg/kg reversed these effects (P < 0.05) (Fig. 4) . In turn, probucol at 3 mg/kg neither restored tissue antioxidant capacity nor reduced reactive oxygen species formation (P > 0.05) (Fig. 4A-D) .
Probucol inhibits LPS-induced cytokine production in the paw skin and peritoneal cavity
Mice were treated with probucol at 3 mg/kg, p.o. or vehicle (Tween 80 5% in saline) 1 h before i.pl. or i.p. administration of LPS (200 ng/ paw). Paw skin samples were removed 3 h post-LPS injection and peritoneal exudates were harvested after 6 h. Samples were processed and homogenized to evaluate TNF-α, IL-6, IL-1β and IFN-γ production by ELISA. Probucol inhibited LPS-induced TNF-α (53% and 54%), IL-6 (40% and 62%), IL-1β (31% and 47%) and IFN-γ (33% and 97%) production in the paw skin and peritoneal cavity, respectively (Fig. 5A-H) .
Probucol inhibits LPS-induced cytokine production in macrophages
RAW 264.7 murine macrophages were treated with probucol (0.05-5 μM) 1 h before stimulation with LPS (1 μg/ml). The supernatants were collected after 6 h and the pro-inflammatory cytokines IL-1β, TNF-α and IL-6 were measured. Probucol at 0.05 μM only inhibited LPS-induced IL-6 levels (36%). The intermediate concentration, 0.5 μM, inhibited the secretion of both IL-6 (52%) and IL-1β (63%). In turn probucol at 5 μM inhibited LPS-induced TNF-α (39%) along with IL-6 (92%) and IL-1β (67%) production (Fig. 6A-C) . Thus, this concentration was chosen to further evaluate whether probucol modulates NF-κB activity in vitro.
3.6. Probucol inhibits LPS-induced NF-кB activation in the paw skin and NF-кB activity in RAW 264.7 macrophages Mice were treated with probucol at 3 mg/kg, p.o. or vehicle (Tween 80 5% in saline) 1 h before i.pl. administration of LPS (200 ng/paw). Paw skin samples were collected 3 h post-LPS injection. Samples were processed and homogenized to evaluate NF-кB activation by ELISA. Probucol inhibited LPS-induced NF-кB activation in paw tissue (39%) demonstrated by a reduction of LPS-induced increase of phosphorylated NF-кB p65/NF-кB p65 ratio (Fig. 7A) . RAW 264.7 murine macrophages expressing luciferase on the NF-кB responsive promoter (pNF-кB-Luc) (3×10 5 cells per well) were treated with probucol at 5 μM 1 h before stimulation with LPS (1 μg/ml). Cell lysates were obtained 6 h after LPS stimulus. NF-кB activity was evaluated by measurement of luciferase activity using the Dual Luciferase Reporter assay system (Promega, WA, USA). Probucol inhibited LPS-induced NF-кB activity (81%) in RAW 264.7 macrophages (Fig. 7B) . Treatment with probucol at 0.05-5 μM did not increase LDH leakage indicating its effects (inhibition of LPS-induced cytokine production and NF-кB activity) were not due to increased cell death (data not shown). This corroborates with previous studies showing that probucol at 1 μM and up to 150 μM does not affect cell viability in BV2 microglial cells or endothelial cells (Chang et al., 2010; Chen et al., 2003) . 
Discussion
Pathogens are first sensed by innate immune cells through recognition of conserved surface molecules generically named pathogenassociated molecular patterns (Medzhitov, 2001) . Tissue resident macrophages play a crucial role in pathogen recognition and subsequently endothelial activation and cell recruitment (Medzhitov, 2008) . Neutrophils, the first cells recruited to the infected tissue, display a wide range of microbicidal mechanisms, such as phagocytosis, degranulation of antimicrobial molecules and formation of neutrophil extracellular traps (Kolaczkowska and Kubes, 2013) . These events briefly summarize the initial immune response evoked to clear the infectious agent. Cellular necrosis and sterile inflammatory signals also activate pattern recognition receptors accounting to the inflammatory response, which can cause tissue lesion (Chen and Nuñez, 2010) . Therefore, the fine-tuning between the necessary protective inflammatory response and excessive inflammation causing tissue lesion is essential. Later, mechanisms of resolution counteract the acute inflammatory response in order to repair tissue damage and reestablish tissue homeostasis (Serhan et al., 2008) . Nonetheless, the persistence of pathogen-associated molecular patterns in the inflammatory milieu further activates macrophages and neutrophils sustaining the inflammatory response. For instance neutrophil-derived mediators and antibiotics promote bacteriolysis leading to release of bacterial components such as LPS. In turn, LPS and other bacterial pathogenassociated molecular patterns boost the immune response contributing . One-way ANOVA followed by Tukey's post-hoc. *P < 0.05 vs. saline group. #P < 0.05 vs. vehicle group. NS stands for non-significant statistical differences.
to the pathophysiology of severe health conditions such as septic shock (Ginsburg, 2002; Ginsburg and Koren, 2008) .
In the present work, we showed that probucol inhibited neutrophil and monocyte recruitment in the peritoneal cavity and paw tissue as well as NF-кB activation and cytokine production. Despite previous studies reporting the antioxidant properties of probucol in different One-way ANOVA followed by Tukey's post-hoc. *P < 0.05 vs. saline group. #P < 0.05 vs. vehicle group. Fig. 6 . Probucol inhibits LPS-induced cytokine production in macrophages. RAW 264.7 macrophages were treated with probucol (0.05-5 μM) or vehicle (Tween 80 5%) 1 h before LPS stimulus (1 μg/ml). Cytokine production was determined in supernatants 6 h after stimulus. Results are expressed as mean ± S.E.M. (n =5 per group per experiment, representative of two separate experiments). One-way ANOVA followed by Tukey's post-hoc. *P < 0.05 vs. saline group. #P < 0.05 vs. vehicle group.
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disease models, we have not observed such effect at the analgesic / anti-inflammatory dose tested (Al-Majed, 2011; Colle et al., 2013; Siveski-Iliskovic et al., 1994) . We attribute this discrepancy to the use of lower doses of probucol administrated in a single treatment opposing to long-term treatments suggesting that probucol displays antioxidant effects in cumulative doses in vivo. In agreement with the present data, in a model of acute brain ischemia, two treatment with probucol at 30 mg/kg, a dose also used in our work, did not reduce superoxide anion production (Park et al., 2007) . Therefore our results suggest that probucol presents anti-inflammatory effects independently of its antioxidant properties in LPS-induced inflammation. Probucol at 3 mg/kg inhibited LPS-induced leukocyte recruitment and hyperalgesia. The mechanisms underlying these effects could be attributed to inhibition of NF-кB activation and cytokine production. LPS triggers NF-кB activation in a Toll-like receptor 4/MyD88-dependent manner leading to the release of TNF-α followed by chemokine (C-X-C motif) ligand 1 (CXCL1) and IL-1β resulting in mechanical hyperalgesia (Calil et al., 2014) . Probucol was shown to inhibit IL-1β-and TNF-α-induced NF-кB translocation to the nucleus in endothelial cells (Chang et al., 2010; Chen et al., 2003) . More recently, Jung et al. (2016) demonstrated the inhibitory effect of probucol over NF-кB by assessing its activity and nuclear translocation. In their study, HEK 293-T cells were treated with probucol at 5 μM 3 h prior exposure to LPS . The present work showed that probucol inhibited LPS-induced NF-кB activation in the paw skin as observed by reduction of the phosphorylated NF-кB p65/total NF-кB p65 ratio. In addition, we have observed a significant reduction in NF-кB activity in probucol-treated RAW 264.7 macrophages stimulated with LPS. In agreement, probucol reduced TNF-α and IL-β levels in both paw tissue and peritoneal cavity as well as in macrophage culture. TNF-α and IL-β directly mediate leukocyte recruitment. These mediators act on endothelial cells through their respective receptors (Tumor necrosis factor receptor 1 and Interleukin-1 Receptor) activating the NF-кB canonical pathway and upregulating adhesion molecules such as E-selectin and Intercellular adhesion molecule 1 (Wyble et al., 1997 (Wyble et al., , 1996 . The activated endothelium favors neutrophil influx, which was previously shown to be dependent on Toll-like receptor /MyD88 signaling in the paw tissue (Calil et al., 2014) and knee joint (Guerrero et al., 2016) in the presence of LPS. In our study, we demonstrated that probucol at 3 mg/kg reduced neutrophil recruitment in the paw tissue by measuring myeloperoxidase activity. In the peritoneal cavity, we also observed a reduction in neutrophil influx by differential cell count and we further confirmed this result by performing immunofluorescence in the mesentery of Lysm-eGFP mice after LPS i.p. injection. Mononuclear recruitment was also inhibited by probucol in both paw tissue and the peritoneal cavity, as demonstrated by the N-acetylglucosaminidase activity assay and differential cell count, respectively. This could be partially attributed to probucol-mediated inhibition of IL-6 and IFN-γ production in the paw tissue and peritoneal cavity. IL-6 plays a role in monocyte migration by increasing endothelial-derived monocyte-attracting chemokines and, along with IFN-γ, IL-6 promotes macrophage differentiation (Chomarat et al., 2000; Hurst et al., 2001; Kaplanski et al., 2003; Munder et al., 1998) . Additionally, probucol was previously shown to inhibit the expression of adhesion molecules by endothelial cells. Low concentrations of probucol (5 μM) inhibited Vascular cell adhesion molecule 1 expression whilst intermediate or higher concentrations (up to 50 μM) were required to inhibit Intercellular adhesion molecule 1 and Eselectin in endothelial cells stimulated with TNF-α or IL-1β (Chang et al., 2010; Chen et al., 2003; Zapolska-Downar et al., 2000) . Our results, in agreement with previous studies, support the hypothesis that probucol exerts its anti-inflammatory effects by targeting the NF-кB pathway. By inhibiting NF-кB activation probucol also impairs the production of its downstream targets, e.g. pro-inflammatory cytokines, culminating in reduced leukocyte recruitment.
We have also demonstrated the analgesic potential of probucol in LPS-induced thermal and mechanical hyperalgesia. Pain is a clinical symptom commonly reported by patients with infectious diseases (Ho et al., 2010; Wadachi and Hargreaves, 2006) . LPS evokes inflammatory hyperalgesia by triggering a cytokine cascade dependent on Toll-like receptor 4/MyD88 downstream signaling. TNF-α is first released and signaling through its receptor triggers CXCL1 and IL-1β production (Calil et al., 2014) . TNF-α and IL-1β also mediate pain signaling by directly sensitizing nociceptors (Binshtok et al., 2008; Jin and Gereau, 2006) . Moreover, IL-1β activates neutrophils leading to production of PGE 2 , a prostanoid shown to mediate mechanical and thermal hyperalgesia through PKA-and PKC-dependent mechanisms Kawabata, 2011) . Increasing evidence has supported the role of IL-6 in pain signaling as well (Cunha et al., 1992; Zhou et al., 2016; Pinho-Ribeiro et al., 2017) . The mechanisms underlying IL-6-induced nociception are not entirely described. For instance, IL-6 levels were shown to be increased in the spinal cord of rats following intraplantar injection of complete Freund's adjuvant (Sun et al., 2012; Xu et al., 2014) . IL-6 was also demonstrated to play a role in nociceptor sensitization as well as central sensitization supporting its participation on pathological pain (Brenn et al., 2007; Obreja et al., 2002; Vazquez et al., 2012) . Therefore inhibition of TNF-α, IL-1β, and IL-6 are likely involved in the analgesic effect of probucol as well. These findings are in agreement with previous studies where probucol also reduced TNF-α, IL-1β and / or IL-6 levels after LPS challenge in murine microglial cells, human peripheral blood mononuclear cells and endothelial cells Meng et al., 2004; Park et al., 2008) . Importantly, probucol-mediated inhibition of cytokine production in the paw tissue, peritoneal cavity and macrophage culture further supports its inhibitory effect on upstream signaling such as the NF-кB pathway.
The present data suggest that probucol is a promising candidate to be further investigated in the management of inflammation and pain. Importantly, the current understanding is that probucol is a safe molecule for clinical use. The human equivalent dose of probucol used in this study according to the conversion table reviewed by Nair and Jacob (2016) would be 0.243 mg/kg, which is lower than the dose (250 and 500 mg pills) clinically approved for the treatment of hypercholesterolemia (Anderson and Schroeder, 1979; Nair and Jacob, 2016) . Additionally, the oral bioavailability of probucol could be further improved by pharmacological formulations, lowering even more the optimal dose for anti-inflammatory / analgesic effects in humans. Fig. 7 . Probucol inhibits LPS-induced NF-кB activation in paw and NF-кB activity in macrophages. Mice received probucol at 3 mg/kg (p.o.) 1 h before i.pl. injection of LPS (200 ng/paw). Paw skin was collected 3 h post injection. NF-кB activation was evaluated by ELISA. The 0 mg/kg of probucol group stands for vehicle group (a). RAW 264.7 macrophages were treated with probucol at 5 μM or vehicle (Tween 80 5%) 1 h before LPS stimulus (1 μg/ml). NF-кB activity was determined in cell lysates 6 h after stimulus (b). Results are expressed as mean ± S.E.M. (n =6 per group per experiment, representative of two separate experiments). One-way ANOVA followed by Tukey's post-hoc. *P < 0.05 vs. saline group. #P < 0.05 vs. vehicle group.
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Conclusion
Taken together our results indicate that probucol presents antiinflammatory and analgesic activities by targeting the NF-кB signaling cascade. We propose that probucol acts on resident immune cells such as macrophages preventing the amplification and persistence of the inflammatory response, which depends on NF-κB-related cytokines. This in turn reduces neutrophil recruitment and induces analgesia (Fig. 8) . Probucol could be a useful anti-inflammatory and analgesic together with antibiotic treatment. Therefore by controlling rather than abrogating the inflammatory response elicited by LPS, our results suggest that probucol is a putative candidate for the treatment of LPSinduced inflammation and hyperalgesia. . Schematic representation of the proposed anti-inflammatory and analgesic mechanisms of probucol. Probucol acts on resident macrophages inhibiting LPS-driven NF-κB activation and cytokine production. As a result, there is reduction of endothelial cell activation and neutrophil recruitment. Neutrophils and macrophages play an important role in nociceptor sensitization by producing pro-hyperalgesic mediators such as PGE 2 and cytokines. Therefore, probucol impairs pain signaling causing analgesia by inhibiting macrophage activation and neutrophil recruitment. In support of these conclusions and present data, previous studies using experimental conditions different from the present study have shown probucol-mediated inhibition of NF-κB activation and well as production and / or expression of IL-1β, TNF-α, IL-6, PGE 2 and adhesion molecules ICAM-1, VCAM-1 and E-selectin (Aoki et al., 2001; Chang et al., 2010; Chen et al., 2003; Li et al., 2011; Liu et al., 2000; Meng et al., 2004; Ozaki et al., 1999; Zhang et al., 2009; Zhang et al., 2013; Zapolska-Downar et al., 2000) . Ca v 3.2 channel, Ca v 3.2 T-type calcium channel. COX-2, cyclooxygenase 2. ICAM-1, Intercellular adhesion molecule 1. IFGNR, IFN-γ receptor. IL-1 β, Interleukin-1β. IL-1R, IL-1β receptor. IL-6, Interleukin-6. LFA-1, Lymphocyte function-associated antigen 1. Na v 1.8 channel, Na v 1.8 voltage-gated Na + channel. PGE 2 , Prostaglandin E 2 . PKA, protein kinase A. PKCε, protein kinase C ε. TLR4, Toll-like receptor 4. TNF-α, Tumor necrosis factor-α. TNFR1, Tumor necrosis factor-α receptor 1. TRPV1, Transient receptor potential vanilloid 1. VCAM-1, Vascular cellular adhesion molecule 1.
